Increase in Superficial Dose in Whole-Breast Irradiation With Halcyon Straight-Through Linac Compared With Traditional C-arm Linac With Flattening Filter: In vivo Dosimetry and Planning Study

Purpose: Superficial dose is an important parameter in breast cancer radiation therapy. When treated with conventional linacs, bolus is commonly applied to improve target coverage near the surface while also managing the risk of severe skin reactions and negative cosmesis. With the introduction of modern linacs with 6X flattening filter free (FFF) photon beams, the effect on superficial dose and the need for bolus must be evaluated. Methods and Materials: In vivo measurements of superficial dose were made with optically stimulated luminescence dosimeters on 11 breast cancer patients treated with the Halcyon 6X FFF linac (Varian Medical Systems, Palo Alto, CA). Additionally, measurements were made with the Halycon 6X FFF beam and a 6X beam with flattening filter (FF) delivered to an anthropomorphic phantom. A planning study was carried out in which 14 patients treated on the Halcyon were replanned with a conventional linac to determine the difference in superficial dose predicted by the treatment planning system. Measures were taken to increase the accuracy of the treatment planning system superficial dose. Results: The use of the Halcyon 6X FFF beam led to higher superficial dose compared with 6X FF beams. The in vivo measurements show an average superficial dose of 83.8% +/- 0.6%, which is an increase of approximately 10% compared with published measurements for a 6X FF linac. Comparison of superficial dose for 6X FF and 6X FFF beams in the phantom measurements show an increase from 70% +/- 1.3% to 84% +/- 1.3%, which is consistent with the in vivo measurements. The planning comparison shows an increase in V70% Rx from 62% +/- 4.4% to 81% +/- 2.2% for the superficial breast tissue for the Halcyon 6X FFF beam compared with a standard C-arm linac with FF. Conclusions: The use of the Halcyon 6X FFF beam was associated with higher superficial dose which may obviate the use of bolus. (C) 2019 The Authors. Published by Elsevier Inc. on behalf of American Society for Radiation Oncology.